血管紧张素Ⅱ受体拮抗剂降蛋白尿及肾脏保护研究进展

doi:10.3969/j.issn.1006-298X.2017.05.016

肾脏病与透析肾移植杂志 ›› 2017, Vol. 26 ›› Issue (5): 467-470.DOI: 10.3969/j.issn.1006-298X.2017.05.016

血管紧张素Ⅱ受体拮抗剂降蛋白尿及肾脏保护研究进展

出版日期:2017-10-28 发布日期:2017-10-27

Advances in the anti proteinuria and kidney protection effect of angiotensin II receptor antagonist

Online:2017-10-28 Published:2017-10-27

摘要/Abstract

摘要：

血管紧张素Ⅱ受体拮抗剂（ARB）是一类作用于肾素血管紧张素系统的降压药物，越来越多的证据表明ARB不仅能降低患者蛋白尿水平，且兼具肾脏保护作用。ARB有别于其降压机制，可通多种途径发挥肾脏保护作用，临床广泛应用于慢性肾脏病、高血压、糖尿病等多种疾病领域。本文就ARB降低蛋白尿及肾脏保护机制及临床实践相关进展做一综述。

Abstract:

Angiotensin II receptor antagonists (ARB) are antihypertensive drugs blocking the reninangiotensin system. Growing evidence proved ARB had kidney protective effect besides the role on proteinuria. Being different from antihypertensive drugs with other mechanisms, ARB could exert kidney protective effect through multiple pathways and is widely used in patients with chronic kidney disease， hypertension or diabetes. This review focuses on proteinurialowing and kidney protective mechanism of ARB, and provides an update about clinical practice.

陈孜瑾,陈晓农. 血管紧张素Ⅱ受体拮抗剂降蛋白尿及肾脏保护研究进展[J]. 肾脏病与透析肾移植杂志, 2017, 26(5): 467-470.

CHEN Zijin,CHEN Xiaonong. Advances in the anti proteinuria and kidney protection effect of angiotensin II receptor antagonist[J]. Chinese Journal of Nephrology, Dialysis & Transplantation, 2017, 26(5): 467-470.

ISSN 1006-298X CN 32-1425/R

血管紧张素Ⅱ受体拮抗剂降蛋白尿及肾脏保护研究进展

Advances in the anti proteinuria and kidney protection effect of angiotensin II receptor antagonist

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 0

编辑推荐

Metrics

本文评价